Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing–remitting multiple sclerosis: the CLARITY Extension study

BACKGROUND: The CLARITY and CLARITY Extension studies demonstrated that treatment of relapsing–remitting multiple sclerosis (RRMS) with cladribine tablets (CT) results in significant clinical improvements, compared with placebo. This paper presents the key magnetic resonance imaging (MRI) findings f...

Descripción completa

Detalles Bibliográficos
Autores principales: Comi, Giancarlo, Cook, Stuart, Rammohan, Kottil, Soelberg Sorensen, Per, Vermersch, Patrick, Adeniji, Abidemi K., Dangond, Fernando, Giovannoni, Gavin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788142/
https://www.ncbi.nlm.nih.gov/pubmed/29399054
http://dx.doi.org/10.1177/1756285617753365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788142/
https://www.ncbi.nlm.nih.gov/pubmed/29399054
http://dx.doi.org/10.1177/1756285617753365

Ejemplares similares